French company’s purchase of Blueprint Medicines boosts immunology pipeline
Anne Wojcicki calls for fresh bankruptcy auction of genetic testing company after Regeneron won bidding
Pharma group estimates Camizestrant could be worth up to $5bn of sales in its peak year
A London-based start-up employs bioprospectors to scour the world for DNA to feed AI models building a digital tree of life
We must recognise and protect the pipelines that lead from research to real-world benefit
Jørgensen’s ousting unusual for group where CEOs have had smooth transitions after long tenures
If successful, it would be the first new class of drug against certain bacteria strains for more than 50 years
The Enhanced Games spotlight a growing interest in drugs not only to improve performance, but also to treat depression
He who understands it, earns it. He who doesn’t, pays it
Companies riding on one big idea should use the good times to plan their next move
The pharma hub stands to lose a lot in the US president’s second term
WHO agreement aims to close resource gaps that undermined Covid response
Being spliced on to Regeneron will free the genetic testing company from its fatal dependence on sporadic revenue
Generics maker Sandoz says president should focus on tactic of ‘evergreening’ pricier products in his drive to lower costs
Drugmaker’s takeover could raise privacy concerns among genetics start-up’s 15mn users
Danish maker of obesity drugs to replace Lars Fruergaard Jørgensen, saying new leadership is needed
Child suffering from rare liver disease shows improved health after treatment
Nice urges NHS to speed up distribution of approved medicines, showing economic benefits of efficient rollout
European Commission president exchanged messages with US pharmaceutical CEO during negotiations for Covid vaccines
Danish company has had some poor results for new drugs designed to replace treatments when they go off patent
US healthcare group brings back former boss Stephen Hemsley
Digital health platform has outperformed but it cannot rely on weight-loss drugs for future success
Net profit falls to €1.3bn as litigation costs and slowing sales weigh on conglomerate
The president seeks to lower US rates in line with other nations but his directive lacks enforcement power
Doctors and pharmacists are using DNA information to tailor treatments
